Analyst Rating Update on Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) : 18 analysts are covering Alexion Pharmaceuticals (NASDAQ:ALXN) and their average rating on the stock is 1.47, which is read as a Strong Buy. 13 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Alexion Pharmaceuticals (NASDAQ:ALXN) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Alexion Pharmaceuticals (NASDAQ:ALXN) has been rated by 15 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $221 and the lowest price target forecast is $145. The average forecast of all the analysts is $193.47 and the expected standard deviation is $24.47.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Morgan Stanley maintains its ratings on Alexion Pharmaceuticals (NASDAQ:ALXN). In the latest research report, Morgan Stanley lowers the target price from $203 per share to $189 per share. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on June 7, 2016.

Alexion Pharmaceuticals (NASDAQ:ALXN): stock turned positive on Tuesday. Though the stock opened at $113, the bulls momentum made the stock top out at $115.69 level for the day. The stock recorded a low of $113 and closed the trading day at $114.94, in the green by 2.73%. The total traded volume for the day was 2,358,599. The stock had closed at $111.89 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, had unloaded 918 shares at an average price of $135.72 in a transaction dated on June 13, 2016. The total value of the transaction was worth $124,591.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *